Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SAT1 | P21673 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | ADH7 | P40394 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26052132 | 1.00 | CYP2C19 (0.55) | CYP2C19CYP1A2KDM1AMEN1KMT2A | |
| SCHEMBL15563084 | 1.00 | CYP2C19 (0.55) | CYP2C19CYP1A2KDM1AMEN1KMT2A | |
| SCHEMBL17780060 | 1.00 | CYP2C19 (0.55) | CYP2C19CYP1A2KDM1AMEN1KMT2A | |
| SCHEMBL11213534 | 1.00 | CYP2C19 (0.55) | CYP2C19CYP1A2KDM1AMEN1KMT2A | |
| SCHEMBL11477230 | 1.00 | CYP2C19 (0.55) | CYP2C19CYP1A2KDM1AMEN1KMT2A | |
| SCHEMBL10712359 | 1.00 | CYP2C19 (0.55) | CYP2C19CYP1A2KDM1AMEN1KMT2A | |
| SCHEMBL10585603 | 1.00 | CYP2C19 (0.55) | CYP2C19CYP1A2KDM1AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2112301 | 0.98 | CYP2C19 (0.52) | CYP2C19CYP1A2KDM1AMEN1KMT2A | |
| SCHEMBL441049 | 0.97 | CYP2C19 (0.57) | CYP2C19CYP1A2KDM1AMEN1KMT2A | |
| SCHEMBL20841975 | 0.91 | LMNA (0.58) | CYP2C19CYP1A2KDM1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210130823-A1 | COMPOSITIONS AND METHODS | IONIS PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-10844379-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| WO-2020027304-A1 | NOVEL CAROTENOID-RELATED DERIVATIVES, AND SALTS, ESTERS, OR AMIDES THEREOF | アスタファーマシューティカルズ株式会社 | 2020-02-06 | — | — | WO | disclosed |
| WO-2019183523-A1 | HETERO-BIFUNCTIONAL DEGRADER COMPOUNDS AND THEIR USE AS MODULATORS OF TARGETED UBIQUINATION (VHL) | GENENTECH, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| CN-109996857-A | Complex ester and monocarboxylic mixture reduce the purposes of friction | 巴斯夫欧洲公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-108611134-A | Polyalkylene glycol for reducing fuel consumption purposes | 巴斯夫欧洲公司 | 2018-10-02 | — | — | CN | disclosed |
| CN-105992810-B | Use of polyalkylene glycols for reducing fuel consumption | 巴斯夫欧洲公司 | 2018-05-25 | — | — | CN | disclosed |
| EP-2809660-B1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORP (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2013116682-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2013-08-08 | — | — | WO | disclosed |
| EP-0031924-B1 | USE OF ALCANOL-AMINE SALTS OF CYCLIC AMIDOCARBOXYLIC ACIDS AS CORROSION INHIBITORS IN AQUEOUS SYSTEMS | BASF Aktiengesellschaft (DE) | 1983-05-18 | — | — | EP | disclosed |
| EP-0031924-A1 | Use of alcanol-amine salts of cyclic amidocarboxylic acids as corrosion inhibitors in aqueous systems | BASF Aktiengesellschaft (DE) | 1981-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | CYP2C19 4884/4885CYP1A2 4861/4885KDM1A 3249/4885 |
| US-20210130823-A1 | COMPOSITIONS AND METHODS | FUT6, FUT5, GNE | CYP2C19 4065/4885CYP1A2 3670/4885KDM1A 3574/4885 |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | VHL, MDM2, CUL2 | CYP2C19 4211/4885CYP1A2 4076/4885KDM1A 1991/4885 |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2C19 3990/4885CYP1A2 3570/4885KDM1A 160/4885 |
| US-10844379-B2 | Conjugated antisense compounds and their use | CSGALNACT1, GALNT1, GALNT6 | CYP2C19 4875/4885CYP1A2 4804/4885KDM1A 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.